5001202026-04-012026-06-305001202026-06-305001202026-04-012026-06-30in-capmkt:OtherExpenses1Member5001202026-04-012026-06-30in-capmkt:ReportableSegments1Member5001202026-04-012026-06-30in-capmkt:ReportableSegments2Member5001202026-04-012026-06-30in-capmkt:ReportableSegments1Member5001202026-04-012026-06-30in-capmkt:ReportableSegments2Member5001202026-04-012026-06-30in-capmkt:ReportableSegments1Member5001202026-06-30in-capmkt:ReportableSegments1Member5001202026-04-012026-06-30in-capmkt:ReportableSegments2Member5001202026-06-30in-capmkt:ReportableSegments2Member5001202026-04-012026-06-30in-capmkt:ReportableSegments1Member5001202026-06-30in-capmkt:ReportableSegments1Member5001202026-04-012026-06-30in-capmkt:ReportableSegments2Member5001202026-06-30in-capmkt:ReportableSegments2Member5001202026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15001202026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25001202026-06-30Statement15001202026-04-012026-06-30Statement15001202026-06-30StatementDynamic1I1Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares500120DIAMINESQNOTLISTEDINE591D01014DIAMINES & CHEMICALS LIMITEDMain BoardEquity2026-04-012027-03-312026-08-052026-07-21INRLakhsQuarterlyFirst quarterMulti segment2026-08-0511:10:002026-08-0513:05:00Not applicabletrue1falseNot Applicable2026-04-012026-06-30UnauditedStandalone1436850006807000150492000782720000-37220002631300023600083800003828100014776000027320000273200000002732000000027320001282100015553000100534000100.270.27000.270.271. The above standalone unaudited financial results have been reviewed and recommended by the Audit Committee and taken on record in its meeting held on 4th August, 2026 and subsequently approved by the Board of Directors of the Company in its meeting held on 05th August, 2026. These standalone unaudited financial results have been reviewed by Statutory Auditors as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. <br /> 2. The Company has two reportable segments i.e. Speciality Chemicals and Trading in Fruits and Vegetables. <br /> 3. The above unaudited standalone financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under section 133 of Companies Act, 2013, read together with the companies (Indian Accounting Standard) Rules, 2015 (as amended). <br /> 4. Figures for the quarter ended March 31,2026 as reported in these standalone financial results are balancing figures between the audited figures in respect of the full financial year and published year to date reviewed figures up to third quarter of the relevant financial year. <br /> Other Expenses38281000Speciality Chemicals143685000Trading in Fruits and Vegetables01436850000143685000Speciality Chemicals2968000Trading in Fruits and Vegetables0296800023600002732000Speciality Chemicals1747836000Trading in Fruits and Vegetables0174783600001747836000Speciality Chemicals96039000Trading in Fruits and Vegetables096039000096039000Gain/(Loss) on measuring equity instruments at Fair Value carried through Other Comprehensive Income (FVTOCI)14804000Remeasurement gain/(loss) on the Defined Benefit Plans134000149380002117000012821000Preferential Issues2026-03-243752450002026-06-30falsefalseNANoneNoneHemaxi PawarCompany SecretaryVadodra2026-08-05capital expenditures, working capital requirements, acquisition, investment in technology and for general corporate purposeNA11153200001115320000The Company had received In-Principle approval on September 19, 2024 for issue not exceeding 916390 number of convertible warrants at Rs. 552 per warrant. The Board, in its meeting held on October 01, 2024, had allotted 906390 convertible warrants on receipt of subscription money Rs. 12.51 crores i.e. 25% of the total Issue, on preferential basis to the investors. Further, out of total issued 906390 warrants, the Company had made allotment of 2,69,402 equity shares (conversion of warrants issued on preferential basis), on receipt of exercise money Rs. 11.15 crores (75% of the issue) by passing board resolution at duly convened board meeting on March 24, 2026, to the applicant from whom entire money has been received and rest all warrants were lapsed as at March 31, 2026 (Last date of conversion of warrants into Equity Shares). Entire Fund has been utilised as on June 30, 2026.